TY - JOUR
T1 - Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities
T2 - Results from two european point prevalence surveys, 2016 to 2017
AU - Healthcare-Associated Infections Prevalence Study Group
AU - Suetens, Carl
AU - Latour, Katrien
AU - Kärki, Tommi
AU - Ricchizzi, Enrico
AU - Kinross, Pete
AU - Moro, Maria Luisa
AU - Jans, Béatrice
AU - Hopkins, Susan
AU - Hansen, Sonja
AU - Lyytikäinen, Outi
AU - Reilly, Jacqui
AU - Deptula, Aleksander
AU - Zingg, Walter
AU - Plachouras, Diamantis
AU - Monnet, Dominique L.
N1 - Publisher Copyright:
© 2018, European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2018/11/15
Y1 - 2018/11/15
N2 - Point prevalence surveys of healthcare-associated infections (HAI) and antimicrobial use in the European Union and European Economic Area (EU/EEA) from 2016 to 2017 included 310,755 patients from 1,209 acute care hospitals (ACH) in 28 countries and 117,138 residents from 2,221 long-term care facilities (LTCF) in 23 countries. After national validation, we estimated that 6.5% (cumulative 95% confidence interval (cCI): 5.4–7.8%) patients in ACH and 3.9% (95% cCI: 2.4–6.0%) residents in LTCF had at least one HAI (country-weighted prevalence). On any given day, 98,166 patients (95% cCI: 81,022–117,484) in ACH and 129,940 (95% cCI: 79,570–197,625) residents in LTCF had an HAI. HAI episodes per year were estimated at 8.9 million (95% cCI: 4.6–15.6 million), including 4.5 million (95% cCI: 2.6–7.6 million) in ACH and 4.4 million (95% cCI: 2.0–8.0 million) in LTCF; 3.8 million (95% cCI: 3.1–4.5 million) patients acquired an HAI each year in ACH. Antimicrobial resistance (AMR) to selected AMR markers was 31.6% in ACH and 28.0% in LTCF. Our study confirmed a high annual number of HAI in healthcare facilities in the EU/EEA and indicated that AMR in HAI in LTCF may have reached the same level as in ACH.
AB - Point prevalence surveys of healthcare-associated infections (HAI) and antimicrobial use in the European Union and European Economic Area (EU/EEA) from 2016 to 2017 included 310,755 patients from 1,209 acute care hospitals (ACH) in 28 countries and 117,138 residents from 2,221 long-term care facilities (LTCF) in 23 countries. After national validation, we estimated that 6.5% (cumulative 95% confidence interval (cCI): 5.4–7.8%) patients in ACH and 3.9% (95% cCI: 2.4–6.0%) residents in LTCF had at least one HAI (country-weighted prevalence). On any given day, 98,166 patients (95% cCI: 81,022–117,484) in ACH and 129,940 (95% cCI: 79,570–197,625) residents in LTCF had an HAI. HAI episodes per year were estimated at 8.9 million (95% cCI: 4.6–15.6 million), including 4.5 million (95% cCI: 2.6–7.6 million) in ACH and 4.4 million (95% cCI: 2.0–8.0 million) in LTCF; 3.8 million (95% cCI: 3.1–4.5 million) patients acquired an HAI each year in ACH. Antimicrobial resistance (AMR) to selected AMR markers was 31.6% in ACH and 28.0% in LTCF. Our study confirmed a high annual number of HAI in healthcare facilities in the EU/EEA and indicated that AMR in HAI in LTCF may have reached the same level as in ACH.
UR - http://www.scopus.com/inward/record.url?scp=85056803564&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2018.23.46.1800516
DO - 10.2807/1560-7917.ES.2018.23.46.1800516
M3 - Article
C2 - 30458912
AN - SCOPUS:85056803564
SN - 1025-496X
VL - 23
JO - Eurosurveillance
JF - Eurosurveillance
IS - 46
M1 - 1800516
ER -